OBJECTIVES: A pilot study was conducted to evaluate the outcomes of breast cancer and its treatment focusing on economic impact and quality of life in a hospital setting METHODS: Patient interviews were held to measure the economic out come and standardized tool EORTC QLQ C 30 and its breast specific module QLQ BR 23 was utilized to measure the quality of life. Twenty-seven subjects diagnosed at different stages of the disease were studied. RESULTS: The respondent’s age ranged between 33-65 yrs with mean age 49.65(SD=9.011). The educational status was classified in to four groups, illiterate to university viz; illiterate (25.92%), primary education (22.22%) secondary education (48.14%), and college studies (3.70%). The marital status of the respondents was classified as married and widowed, 81.48% and 18.51% respectively. The distribution of respondents according to TNM staging of breast cancer was observed as first stage (none), stage II (29.62%), stage III (40.74%), and stage IV (14.81%). All patients were treated with a multimodality approach for management. The cost analysis revealed that there are significant differences among different modalities of treatments viz; module one (Rs.1.00 lakh), module two (Rs.1.57 lakh) and module three (Rs.1.09 lakh).The quality of life study revealed that there are differences in the functional scales as well as symptoms scales among the patients treated with different treatment regimens. CONCLUSIONS: Breast cancer is a disease, where there is a lot of scope for pharmaceutical care in order to improve the functional scales and global health and to decrease symptoms scales of breast cancer patients. Key words; Breast cancer, outcomes, quality of life